ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Update

ENDRA Life Sciences Inc. (NASDAQ:NDRA) saw a significant drop in short interest during the month of July. As of July 15th, there was short interest totaling 27,635 shares, a drop of 34.4% from the June 30th total of 42,119 shares. Based on an average daily trading volume, of 36,764 shares, the short-interest ratio is presently 0.8 days. Approximately 2.4% of the shares of the company are sold short.

Analysts Set New Price Targets

NDRA has been the subject of a number of recent analyst reports. Ascendiant Capital Markets decreased their target price on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Weiss Ratings raised shares of ENDRA Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, ENDRA Life Sciences currently has an average rating of “Hold” and a consensus price target of $25.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in ENDRA Life Sciences stock. Altium Capital Management LLC purchased a new stake in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences comprises about 0.9% of Altium Capital Management LLC’s investment portfolio, making the stock its 17th biggest holding. Altium Capital Management LLC owned approximately 6.92% of ENDRA Life Sciences as of its most recent filing with the SEC. Hedge funds and other institutional investors own 1.19% of the company’s stock.

ENDRA Life Sciences Trading Up 8.9%

Shares of NDRA opened at $4.71 on Friday. The firm has a fifty day simple moving average of $4.99 and a two-hundred day simple moving average of $4.61. The firm has a market cap of $5.99 million, a PE ratio of -0.58 and a beta of -0.06. ENDRA Life Sciences has a 1-year low of $2.96 and a 1-year high of $9.85.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings results on Friday, May 15th. The company reported ($1.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.14. As a group, research analysts forecast that ENDRA Life Sciences will post -4.11 EPS for the current fiscal year.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.